David A. Siegel Nektar Therapeutics Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Nektar Therapeutics stock. As of the latest transaction made, Two Sigma Advisers, LP holds 2,240,342 shares of NKTR stock, worth $2.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,240,342

Previous 3,069,542 27.01%

Holding current value

$2.78 Million

Previous $1.72 Million 21.25%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.49 - $0.96 $406,308 - $796,032	-829,200 Reduced 27.01%	2,240,342 $2.08 Million
Q4 2023 Feb 14, 2024	SELL	$0.42 - $0.57 $285,558 - $387,542	-679,900 Reduced 18.13%	3,069,542 $1.72 Million
Q3 2023 Nov 14, 2023	SELL	$0.51 - $1.05 $27,591 - $56,805	-54,100 Reduced 1.42%	3,749,442 $2.25 Million
Q2 2023 Aug 14, 2023	BUY	$0.53 - $1.03 $667,376 - $1.3 Million	1,259,200 Added 49.49%	3,803,542 $2.21 Million
Q1 2023 May 15, 2023	BUY	$0.64 - $3.15 $1.29 Million - $6.33 Million	2,010,700 Added 376.79%	2,544,342 $1.78 Million

Q4 2022 Feb 14, 2023	SELL	$2.03 - $4.28 $202,999 - $428,000	-100,000 Reduced 15.78%	533,642 $1.21 Million
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $1.43 Million - $2.41 Million	469,100 Added 285.09%	633,642 $2.03 Million
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $3,170 - $6,170	1,000 Added 0.61%	164,542 $625,000
Q1 2022 May 16, 2022	SELL	$4.16 - $13.72 $210,080 - $692,860	-50,500 Reduced 23.59%	163,542 $881,000
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $1.87 Million - $3.17 Million	172,400 Added 414.01%	214,042 $2.89 Million
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $300,610 - $433,320	23,000 Added 123.38%	41,642 $748,000
Q2 2021 Aug 16, 2021	SELL	$16.52 - $20.4 $77,644 - $95,880	-4,700 Reduced 20.14%	18,642 $320,000
Q1 2021 May 17, 2021	BUY	$16.56 - $25.46 $46,368 - $71,288	2,800 Added 13.63%	23,342 $467,000
Q4 2020 Feb 16, 2021	SELL	$15.77 - $19.03 $392,673 - $473,847	-24,900 Reduced 54.8%	20,542 $349,000
Q3 2020 Nov 16, 2020	BUY	$16.59 - $24.79 $560,742 - $837,902	33,800 Added 290.33%	45,442 $754,000
Q2 2020 Aug 14, 2020	BUY	$16.86 - $23.44 $196,284 - $272,888	11,642 New	11,642 $270,000
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $356,569 - $688,990	-24,642 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$15.87 - $23.12 $391,068 - $569,723	24,642 New	24,642 $532,000
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $488,605 - $717,127	-15,472 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $7.52 Million - $14 Million	-247,242 Reduced 94.11%	15,472 $509,000
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $2.21 Million - $3.26 Million	-47,600 Reduced 15.34%	262,714 $16 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $14.4 Million - $32.4 Million	310,314 New	310,314 $15.2 Million
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $3.32 Million - $6.27 Million	-57,814 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $238,441 - $626,659	-10,358 Reduced 15.19%	57,814 $3.45 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $1.21 Million - $1.64 Million	68,172	68,172 $1.64 Million

Others Institutions Holding NKTR

# of Institutions

128

Shares Held

111M

Call Options Held

150K

Put Options Held

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $232M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account